{
    "nct_id": "NCT06103838",
    "official_title": "A Phase II Trial Evaluating 18F-Fluciclovine PET/CT in Multiple Myeloma",
    "inclusion_criteria": "* INCLUSION CRITERIA:\n* Participants must have a documented diagnosis of MM defined by the IMWG Criteria. Participants at diagnosis must have had a serum M-protein >= 3 g/dL and/or bone marrow plasma cells >= 10% and at least one of the following:\n\n  * Anemia: Hemoglobin <=10 g/dL, or\n  * Renal Failure: serum creatinine >= 2.0 mg/dL, or\n  * Hypercalcemia: Ca >= 10.5 mg/dL, or\n  * Lytic bone lesions on X-ray, CT, or PET/CT, or\n  * >= 2 focal lesions on spinal MRI, or\n  * >= 60% bone marrow plasma cells, or\n  * Involved/un-involved serum free light chain ration >= 100\n* Participants must have measurable disease defined by any one of the following:\n\n  * Monoclonal bone marrow plasma cells > 5%\n  * Serum monoclonal protein >= 0.2 g/dl\n  * Urine monoclonal protein > 200 mg/24 hr\n  * Serum immunoglobulin free light chain > 10 mg/dL AND abnormal kappa/lambda ratio\n  * A measurable lesion on PET/CT or MRI\n* Participants fit criteria for one of the following categories:\n\n  * Newly diagnosed multiple myeloma (NDMM)\n  * Relapsed and/or refractory multiple myeloma (RRMM) with at least 1 prior line of therapy\n* Age >=18 years.\n* ECOG performance status <= 2\n* Negative serum or urine pregnancy test at screening for WOCBP.\n* Women of child-bearing potential and men must agree to use effective contraception (hormonal or barrier method of birth control; abstinence) 24 hours prior to and for the 24 hours after each 18F-fluciclovine administration.\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-FDG\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to 18F-fluciclovine or other similar agents.\n* Subjects with severe claustrophobia unresponsive to oral anxiolytics or unwilling to take them.\n* Uncontrolled intercurrent illness including, psychiatric illness/social situations that would limit compliance with study requirements.\n* Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with 18F-fluciclovine, breastfeeding should be discontinued if the mother is treated with 18F-fluciclovine until 3 days after 18F-fluciclovine.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 120 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}